A Multicenter, Postmarketing Study to Evaluate the Concentration of Certolizumab Pegol in the Breast Milk of Mothers Receiving Treatment With Cimzia (Certolizumab Pegol)

Trial Profile

A Multicenter, Postmarketing Study to Evaluate the Concentration of Certolizumab Pegol in the Breast Milk of Mothers Receiving Treatment With Cimzia (Certolizumab Pegol)

Completed
Phase of Trial: Phase I

Latest Information Update: 14 Sep 2017

At a glance

  • Drugs Certolizumab pegol (Primary)
  • Indications Ankylosing spondylitis; Crohn's disease; Psoriatic arthritis; Rheumatoid arthritis; Spondylitis
  • Focus Adverse reactions; Pharmacokinetics
  • Acronyms CRADLE
  • Sponsors UCB
  • Most Recent Events

    • 14 Sep 2017 According to an UCB media release, data from the study were presented at the 26th European Academy of Dermatology and Venereology (EADV) Congress.
    • 16 Aug 2017 Results published in the Annals of the Rheumatic Diseases
    • 17 Jun 2017 Results presented at the 18th Annual Congress of the European League Against Rheumatism
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top